Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina

PHASE2CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2010

Conditions
Angina Pectoris
Interventions
DRUG

T89

A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.

Trial Locations (15)

14221

Marc Kozinn Associates, Williamsville

23502

National Clinical Research-Norfolk, Inc, Norfolk

29201

Three Rivers Medical Associates, Columbia

33173

Cardiovascular Research Center of South Florida, Miami

33319

Sunrise Medical Research, Lauderdale Lakes

48706

Great Lakes Research Group, Inc, Bay City

53719

Gemini Scientific, LLC, Madison

71301

Alexandria Cardiology Clinic, Alexandria

73132

Oklahoma Cardiovascular & Hypertension, Oklahoma City

77002

East Texas Cardiology, Houston

77070

Northwest Houston Cardiology, Houston

77375

Northwest Heart Center, Tomball

85705

Paradigm Clinical, Inc., Tucson

90211

Robert M. Karns, A Medical Corporation, Beverly Hills

92879

Inland Heart Doctors, Corona

All Listed Sponsors
lead

Tasly Pharmaceuticals, Inc.

INDUSTRY

NCT00797953 - Phase II Multi-Center Study of T89 to Treat Chronic Stable Angina | Biotech Hunter | Biotech Hunter